Sarcoidosis with musculoskeletal manifestations: systematic review of non-pharmacological and pharmacological treatments

Abstract

We aimed to summarise effects and use of non-pharmacological and pharmacological treatments for sarcoidosis with musculoskeletal manifestations. We systematically searched the Cochrane Library, Ovid MEDLINE, Embase, CINAHL, AMED, Scopus, clinical.trials.gov, PROSPERO and PEDro for systematic reviews from 2014 to 2022 and for primary studies from date of inception to March 29, 2022, and studies with patients diagnosed with sarcoidosis with musculoskeletal manifestations. Inclusion criteria required that studies reported effects of non-pharmacological and/or pharmacological treatments or number of patients receiving these treatments. Results were reported narratively and in forest plots. Eleven studies were included. No systematic reviews fulfilled our inclusion criteria. None of the included studies had a control group. We found that between 23 and 100% received corticosteroids, 0–100% received NSAIDs, 5–100% received hydroxychloroquine, 12–100% received methotrexate, 0–100% received TNF inhibitors, and 3–4% received azathioprine. Only ten patients in one study had used non-pharmacological treatments, including occupational therapy, chiropractic and acupuncture. There are no controlled studies on treatment effects for patients with sarcoidosis with musculoskeletal manifestations. We found 11 studies reporting use of pharmacological treatments and only one study reporting use of non-pharmacological treatments. Our study identified major research gaps for pharmacological and non-pharmacological treatment in musculoskeletal sarcoidosis and warrant randomised clinical trials for both.

Vertebral sarcoidosis: diagnosis to management

“…In nonresponsive patients, the use of conventional immunosuppressive drugs is more anecdotal. Methotrexate (7.5 to 15 mg per week) is the most used in musculoskeletal sarcoidosis as a GC-saving agent (39). Other conventional synthetic disease modifying antirheumatic drugs (csDMARDs) such as hydroxychloroquine showed to be effective for the management of vertebral sarcoidosis Studies based on single cases or small series revealed encouraging results.…”